- ROUNDTABLE: Pharmacy’s future in sync with technology
- Senate passes Drug Quality and Security Act
- 21 health industry groups address FDA on proposed changes to generic drug label rules
- GPhA: FDA’s proposed rule on prescription drug labeling adds $4 billion to healthcare costs
- Roxane Labs' generic prostate drug gets tentative approval from FDA
SILVER SPRING, Md. - The Food and Drug Administration has given tentative approval to a generic drug for treating hypertension, according to agency records.
The FDA granted tentative approval to Dr. Reddy's Labs' valsartan tablets in the 40 mg, 80 mg, 160 mg and 320 mg strengths.
The drug is a generic version of Novartis' Diovan. Various versions of the drug had sales of $1.6 billion during the 12-month period that ended in June, according to IMS Health.
Tentative approval means that a drug meets the FDA's conditions for approval, but the agency can't give it final approval due to patent or exclusivity issues.
In early January 2013, the U.S. District Court for the District of Columbia upheld an FDA decision protecting Ranbaxy Labs' market exclusivity for its generic valsartan tablets.
Find us on Facebook for more insight, analysis and the latest in drug store news.